Response of uveal metastases to alk inhibitors in alk-positive non–small-cell lung cancer

Conclusion: ALK inhibitors are an effective first-line treatment in patients with ALK-positive uveal metastases secondary to ALK-positive non–small-cell lung cancer. Despite the fact that crizotinib, a first-generation ALK inhibitor, is initially effective in dealing with non–small-cell lung cancer and its metastases, resistance to it seems to develop on a regular basis. A second-generation ALK inhibitor, such as ceritinib, is also effective in overcoming this resistance in treating those with ALK-positive uveal metastases.
Source: Retinal Cases and Brief Reports - Category: Opthalmology Tags: Case Report Source Type: research